Abstract:Cancer therapy targets specific metabolic pathways or a single gene. This may result in low therapeutic effects due to drug selectivity and drug resistance. Recent studies revealed that the mitochondrial membrane potential and transmembrane permeability of cancerous mitochondria are differed from normal mitochondria. Thus, chemotherapy targeting cancerous mitochondria could be an innovative and competent strategy for cancer therapy. Previously, our work with a novel group of mitochondria targeting small molecules presented promising inhibitory capability toward various cancer cell lines and suppressed adenosine triphosphate (ATP) generation. Therefore, it is critical to understand the anticancer effect and targeting mechanism of these small molecules. This study investigated the inhibitory activity of mitochondria targeting small molecules with human cervical cancer cells - HeLa to further explore their therapeutic potential. HeLa cells were exposed to 10 mu M of syn-thesized compounds and presented elevation in intracellular reactive oxygen species (ROS) level, impaired mitochondrial membrane potential and upregulation of apoptosis as well as necrosis. In vivo, HeLa cell tumor-bearing BALB/c nude mice were treated with mitochondria targeting small molecules for 12 days consecu-tively. Throughout this chemotherapy study, no deleterious side effects nor the appearance of toxicity was observed. Furthermore, mitochondria targeting small molecules treated groups exhibited significant down-regulation with both tumor volume and tumor weight compared to the Doxorubicin (DOX) treated group. Thus, inhibition of mitochondrial ATP synthesis, activation of intracellular ROS production, down-regulation of mitochondrial membrane potential and upregulation of apoptosis and necrosis rates are the indications of cancer therapy. In this work, we examined the anticancer capability of four mitochondria targeting small molecules in vitro and in vivo, and demonstrated a novel therapeutic approach in cancer therapy with tremendous potential.

Advances of antineoplastic agents based on mitochondrial targeting mechanism

Mitochondria-Shaping Proteins and Chemotherapy

Targeted Mitochondrial Nanomaterials in Biomedicine: Advances in Therapeutic Strategies and Imaging Modalities

Recent Advancements in Mitochondria-Targeted Nanoparticle Drug Delivery for Cancer Therapy

Research Progress on Mitochondria Regulating Tumor Immunity.

Recent advances in mitochondria-targeting theranostic agents

Advancements in nano drug delivery system for liver cancer therapy based on mitochondria-targeting

Small Mitochondria-Targeting Molecules As Anti-Cancer Agents

Mitochondria-Targeted Nanomedicine for Enhanced Efficacy of Cancer Therapy

Mitochondrial-Targeting Anticancer Agent Conjugates and Nanocarrier Systems for Cancer Treatment

Application Prospects of Triphenylphosphine-Based Mitochondria-Targeted Cancer Therapy

Multifunctional Mitochondria-Targeting Nanosystems for Enhanced Anticancer Efficacy

Biological Evaluation of Mitochondria Targeting Small Molecules As Potent Anticancer Drugs.

Mitochondria-Targeted Nanocarriers Promote Highly Efficient Cancer Therapy: A Review

Recent Progress in Mitochondria-Targeted Drug and Drug-Free Agents for Cancer Therapy

Mitochondria-targeted cancer therapy based on functional peptides

Mitochondria as a Novel Target for Cancer Chemoprevention: Emergence of Mitochondrial-targeting Agents

Mitocans Revisited: Mitochondrial Targeting as Efficient Anti-Cancer Therapy

Mitochondria in tumor immune surveillance and tumor therapies targeting mitochondria

The role of mitochondria in tumor metastasis and advances in mitochondria-targeted cancer therapy

Mitochondria: a new intervention target for tumor invasion and metastasis